Study on Juvenile Idiopathic Arthritis patients treated with biological therapy at the National Musculoskeletal Institute
Sütő (Orbán) Ilonka
Molecular Medicine
Dr. Enyedi Péter
ORFI Lukács épület előadóterem
2024-03-11 14:30:00
Immunology
Dr. Poór Gyula
Dr. Kiss Emese
Dr. Kriván Gergely
Dr. Sümegi Viktória
Dr. reusz György
Dr. Ujfalussy Ilona
Dr. Szabó András lajos
Dr. Hidvégi Bernadett
Dr. Rojkovich Bernadette
Study on Juvenile Idiopathic Arthritis patients treated with biological therapy at the National Musculoskeletal Institute
JIA is a rare but serious condition that, if left untreated, can lead to disability. My goal for my PhD research was to look into the relationship between demographics, disease subgroups, the genetic and immunological background of the disease, disease baseline activity of JIA patients treated with biologic therapy from the early beginning, using data from my real-world clinical experience. I investigated the efficacy and safety of the first biologic therapy in the long term using ACR Pedi and cJADAS10 values, as well as the outcome of disease activity, the improvement of ACR Pedi up to 18 years of age, and the activity level and disability status according to CHAQ of patients who reached adulthood.
My thesis contains a prospective analysis of the disease progression of the JIA patients with a polyarticular course, receiving the first biological therapy in the National Musculoskeletal Institute between January 1, 2002 and December 31, 2020, taking into consideration Hungarian prescribing guidelines.
In the every practice, I was the first in Hungary to analyze the data of a wide range of real-life JIA patients getting biological therapy, utilizing measuring methods that can be used to measure therapeutic effect and judge disease activity, which are suitable for international comparison and further research. I confirmed that biological therapy is effective and safe in the long term. Its effectiveness depends on the phenotype differences characteristic of JIA, the onset of the disease, the time of diagnosis, the previous methotrexate treatment, the start date of biological therapy, not least the genetic and immunological background of the disease.
